Aptus Pharma Preferential Issue (12 Nov 2026)
Aptus Pharma Limited allotts 15,97,470 equity shares on preferential basis dated 12-11-2026
Aptus Pharma · Pharmaceuticals & Biotechnology
Key highlights
- Allotment of 15,97,470 fully paid-up equity shares of ₹10 each at ₹280 per share, raising ₹44.73 crore
- Issued shares increased company’s paid-up capital from ₹17.15 crore to ₹18.75 crore as of 12 Nov 2026
- Shares allotted to 188 allottees including public and promoter groups, per shareholder approval on 14 Sept 2026
Original filing
Board Meeting Outcome for Outcome Of Board Meeting - Allotment Of Equity Shares On Preferential Basis Under Regulation 30 Of SEBI LODR Regulations, 2015
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Aptus Pharma
- Fundraise / allotmentNotableAptus Pharma receives BSE in-principle approval for preferential equity issue
Other fundraise / allotment filings this fortnight
- Fundraise / allotmentJTL DefenceJTL Defence schedules Rights Issue Committee meeting for November 17, 2026
- Fundraise / allotmentAGI InfraAGI Infra Limited announces closure of trading window from Nov 12, 2026
- Fundraise / allotmentTD Power SystemsTD Power Systems Ltd announces Q2 2026 results, preferential share allotment and dividend
- Fundraise / allotmentHighness MicroelectronicsHighness Microelectronics Limited proposes preferential issue of 3.44 lakh equity shares
- Fundraise / allotmentIndian EmulsifiersIndian Emulsifiers Limited files newspaper advertisement for Rights Issue of ₹51 crore
- Fundraise / allotmentAlphageo (India)Alphageo (India) Limited reports Q2 and H1 FY 2026 unaudited financial results
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.